CompletedNCT00277212
Aripiprazole added to lamotrigine for long-term bipolarity maintenance
About this title
A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode
Read the official source — NCT00277212Medication studyAges 18+United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 65 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: December 1, 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 1,169
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT00277212
- Official title
Show the full official title
A Multicenter, Double-blind, Study of the Efficacy and Safety of Aripiprazole in Combination With Lamotrigine in the Long-term Maintenance Treatment of Patients With Bipolar I Disorder With a Recent Manic or Mixed Episode
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham, United States · Tucson, United States · Anaheim, United States
59 more locations
- Costa Mesa, United States
- Los Angeles, United States
- Oceanside, United States
- Pasadena, United States
- Stanford, United States
- Torrance, United States
- Upland, United States
- Boca Raton, United States
- Coral Springs, United States
- Daytona Beach, United States
- Fort Myers, United States
- Miami, United States
- Port Charlotte, United States
- West Palm Beach, United States
- Atlanta, United States
- Greenwood, United States
- Terre Haute, United States
- Prairie Village, United States
- Wichita, United States
- Lexington, United States
- Owensboro, United States
- Baltimore, United States
- Glen Burnie, United States
- Rockville, United States
- Farmington Hills, United States
- Minneapolis, United States
- Saint Paul, United States
- Flowood, United States
- Cherry Hill, United States
- Buffalo, United States
- Rochester, United States
- Staten Island, United States
- Durham, United States
- Raleigh, United States
- Bismarck, United States
- Canton, United States
- Cincinnati, United States
- Cleveland, United States
- Oklahoma City, United States
- Portland, United States
- Allentown, United States
- DuBois, United States
- East Stroudsburg, United States
- Philadelphia, United States
- Memphis, United States
- Nashville, United States
- Piney Flats, United States
- Houston, United States
- San Antonio, United States
- Charlottesville, United States
- Virginia Beach, United States
- Bothell, United States
- Seattle, United States
- Morgantown, United States
- Milwaukee, United States
- Cabo Rojo, Puerto Rico
- Ponce, Puerto Rico
- Rio Piedras, Puerto Rico
- San Juan, Puerto Rico
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Lamotrigine + Aripiprazole and Lamotrigine + Placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
